Managing Thrombosis in Cancer Patients

Video

This video reviews recommendations for the prevention and management of thrombosis in patients with cancer.

Cancer patients have a two- to three-fold risk of bleeding compared with the general population.

In this video, Michael Streiff, MD, of Johns Hopkins School of Medicine, discusses recommendations for the prevention and management of thrombosis in patients with cancer.

Streiff also reviews the risks of long-term use of the anticoagulant heparin, including the possibility of an increased of osteoporosis.

Related Videos
Caitlin Costello, MD, with the Oncology Brothers
Caitlin Costello, MD, with the Oncology Brothers
Caitlin Costello, MD, with the Oncology Brothers
Caitlin Costello, MD, with the Oncology Brothers
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
Collaboration among nurses, social workers, and others may help in safely administering outpatient bispecific T-cell engager therapy to patients.
Immunotherapy may be an “elegant” method of managing colorectal cancer, says Gregory Charak, MD.
D. Ross Camidge, MD, PhD, spoke about how the approval of alectinib is the beginning of multiple other approvals for patients with ALK-positive NSCLC.
Related Content
65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices

65 Racial Disparities in Treatment Patterns and Outcomes Among HER2-Low Metastatic Breast Cancer Patients Treated in US Community Oncology Practices

May 7th 2024
Article
Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Administering CAR T-Cell Therapy and Bispecific Agents in Nursing Practice

May 6th 2024
Podcast

Registered nurses discuss research related to agents like ciltacabtagene autoleucel presented at the 2024 Oncology Nursing Society Congress.

Data from the phase 1/2 eNRGy trial support the biologics license application for zenocutuzumab in NRG1-positive NSCLC and PDAC.

Zenocutuzumab Earns FDA Priority Review in NRG1+ NSCLC, Pancreatic Cancer

May 7th 2024
Article

Data from the phase 1/2 eNRGy trial support the biologics license application for zenocutuzumab in NRG1-positive NSCLC and PDAC.

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

Applying Novel Radiotherapy Technology for Brain Tumors and Other Cancers

April 29th 2024
Podcast

Timothy Chen, MD, highlights how technologies such as ZAP-X and proton therapy may improve outcomes for patients with cancer.

All patients with a response to TAR-200 did not have progression to muscle-invasive bladder cancer or metastatic disease in the SunRISe-1 trial.

Lasting Responses Observed With TAR-200 in BCG-Unresponsive NMIBC

May 7th 2024
Article

All patients with a response to TAR-200 did not have progression to muscle-invasive bladder cancer or metastatic disease in the SunRISe-1 trial.

CheckMate-8HW assessed the efficacy of first-line nivolumab plus ipilimumab in patients with MSI-H/dMMR metastatic colorectal cancer.

Nivolumab/Ipilimumab Receive Type II Validation by EMA in MSI-H/dMMR mCRC

May 6th 2024
Article

CheckMate-8HW assessed the efficacy of first-line nivolumab plus ipilimumab in patients with MSI-H/dMMR metastatic colorectal cancer.